VistaGen Therapeutics
VTGN
17 hedge funds and large institutions have $5.23M invested in VistaGen Therapeutics in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
88% more capital invested
Capital invested by funds: $2.79M → $5.23M (+$2.44M)
21% more funds holding
Funds holding: 14 → 17 (+3)
0.18% more ownership
Funds ownership: 0.54% → 0.72% (+0.18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.33M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$918K |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$208K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$65.2K |
| 5 |
AWCI
Alpine Woods Capital Investors
Purchase,
New York
|
+$49.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$255K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$65K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$21K |
VTGN Hedge Fund Activity: Q4 2017 in Review
17 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2017, worth a combined $5.23M — up 88% from $2.79M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTGN positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $2.33M. The largest seller was Parallax Volatility Advisers, cutting an estimated $255K.
- 17 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2017, up from 14 in Q3 2017.
- Funds reported $5.23M of VistaGen Therapeutics stock for Q4 2017, up 88% quarter-over-quarter.
- 6 funds opened new VistaGen Therapeutics positions in Q4 2017 and 3 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q4 2017 was Sabby Management, an estimated $2.33M added.
- The largest VistaGen Therapeutics seller in Q4 2017 was Parallax Volatility Advisers, an estimated $255K sold.
Based on aggregated 13F filings for Q4 2017.